Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy
Authors:
- Eleonora RussoEleonora Russo
- Simona CorraoSCSimona Corrao
- Francesca Di GaudioFGFrancesca Di Gaudio
- Giusi AlbertiGAGiusi Alberti
- Martin CaprndaMCMartin Caprnda
- Peter KubatkaPeter Kubatka
- Peter KruzliakPeter Kruzliak
- Vitale MiceliVMVitale Miceli
- Pier Giulio ConaldiPCPier Giulio Conaldi
- Cesario Venturina BorlonganCesario Venturina Borlongan
- Giampiero La RoccaGiampiero La Rocca
Open Access
Abstract
Coronavirus disease 2019 (COVID-19), the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which counts more than 650 million cases and more than 6.6 million of deaths worldwide, affects the respiratory system with typical symptoms such as fever, cough, sore throat, acute respiratory distress syndrome (ARDS), and fatigue. Other nonpulmonary manifestations are related with abnormal inflammatory response, the “cytokine storm”, that could lead to a multiorgan disease and to death. Evolution of effective vaccines against SARS-CoV-2 provided multiple options to prevent the infection, but the treatment of the severe forms remains difficult to manage. The cytokine storm is usually counteracted with standard medical care and anti-inflammatory drugs, but researchers moved forward their studies on new strategies based on cell therapy approaches. The perinatal tissues, such as placental membranes, amniotic fluid, and umbilical cord derivatives, are enriched in mesenchymal stromal cells (MSCs) that exert a well-known anti-inflammatory role, immune response modulation, and tissue repair. In this review, we focused on umbilical-cord-derived MSCs (UC-MSCs) used in in vitro and in vivo studies in order to evaluate the weakening of the severe symptoms, and on recent clinical trials from different databases, supporting the favorable potential of UC-MSCs as therapeutic strategy.Keywords
Funding Information
- Università degli Studi di Palermo (FFR 2022-2023, 2017RSAK7_003)
- Italian Ministry of Research and University (MIUR) (FFR 2022-2023, 2017RSAK7_003)
This publication has 251 references indexed in Scilit:
- Muscle stem cells in developmental and regenerative myogenesisCurrent Opinion in Clinical Nutrition and Metabolic Care, 2010
- Human Hsp10 and Early Pregnancy Factor (EPF) and their relationship and involvement in cancer and immunity: Current knowledge and perspectivesLife Sciences, 2010
- Mesenchymal Stem Cells Derived from Dental Tissues vs. Those from Other Sources: Their Biology and Role in Regenerative MedicineJournal of Dental Research, 2009
- Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass EffectStem Cells and Development, 2009
- Isolation and Characterization of Adult Stem Cells from Human Salivary GlandsStem Cells and Development, 2008
- Native Umbilical Cord Matrix Stem Cells Express Hepatic Markers and Differentiate Into Hepatocyte-like CellsGastroenterology, 2008
- Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapiesMechanisms of Ageing and Development, 2008
- Isolation of amniotic stem cell lines with potential for therapyNature Biotechnology, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based TherapiesTissue Engineering, 2001